

CARDIOLOGY  
2025 

**Mechanical Circulatory Support  
The Road to Explant**

**Christy Bosler MS PA-C**  
February 21, 2025

 **Children's Hospital  
of Philadelphia®**  
Cardiac Center

**HOPE. HEAL. LEARN.**



# VENTRICULAR ASSIST DEVICE

Berlin Heart EXCOR<sup>®</sup>

2008 approved for an investigational device

2011 approved for pediatrics

HeartMate 3

2017 Approved

patients >25 to 30 kg

Timely implantation

Preserve & recover end-organ function

Increased focus on post-implant management



# WHO

Myocarditis

Dilated Cardiomyopathy

Tachyarrhythmias

Mechanical unloading VAD → myocardial recovery

# WHO

VAD Explants UNCOMMON

1% Adults (126)

Limited Pediatric info ~35 patients

Higher Likelihood for Myocardial Recovery

- < Age
- < Duration
- Non-ischemic CM
- Medications
- Surveillance
- Weaning Protocols

**“Myocardial recovery exists, but one must look for it and strive to obtain it”**

# WHO


## CHOP Explants

2016 - 2022 3 patients

2023- 2025 10 patients

- Age 10 months- 17ys
- DCM (5)
- Myocarditis
- ALCAPA
- Ischemic CM
- Tachycardia induced CM (2)

## VAD Explants



# WHAT CHANGED

- Myocardial Function Recovery (MFR) is possible  
pt < 2yrs with Goal Directed Medical Therapy  
Vigilance
- Bivalirudin significantly lower hospital mortality, is cost-effective therapy  
used in 90% pediatric VADs
- Early VAD patients had significantly higher survival rate as compared to ECMO



# WHO

1. All patients are candidates for recovery
2. Attention to reverse modeling
3. Protocolized Assessment
4. Regular Review



# REVERSE MODELING MEDICATIONS

## Goal of Cardiac Remodeling Medications

- Ventricular Dilation
- Fibrosis
- Contractility

## Guideline-Directed Medical Therapy (GDMT)

- Beta-Blocker
- ACEi or
- ARB or
- ARNi
- Plus: Aldactone, Digoxin, SGLT-2 Inhibitor



ACTION Medication-Outcome-Tension Frequency & Follow-Up Considerations						
	Medication(s) of choice	Time to onset (days/weeks)	Frequency	BP	HR	Notes
long-term therapy	Thiazide	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
	Thiazide	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
	Thiazide + ACE inhibitor	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
	Thiazide + ACE inhibitor	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
	Thiazide + ACE inhibitor	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
long-term therapy	Thiazide	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
	Thiazide	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
	Thiazide + ACE inhibitor	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
	Thiazide + ACE inhibitor	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients
	Thiazide + ACE inhibitor	1-2 weeks	1	15 mmHg or greater reduction in systolic blood pressure	10	Heart failure patients

CARDIOLOGY  
2025 

# VAD PROTOCOLS

## VAD Weaning Protocols

April 2023

Systematic approach

Determine readiness

1. Berlin ECHO Turndown Protocol
2. Berlin Cath Turndown Protocol
3. HeartMate3 Explant Protocol



Catherine Montgomery



Carol A. Wittlieb-Weber, MD



Jonathan B. Edelson, MD



Lynne Ha

# VAD TURNDOWN

## Eligibility Criteria

- Monthly ECHOs
- Good Function = Consecutive weans, monthly checks
- LVEDD WNL Z score between -2 +2
- EF of 45% with  $\leq$  mild dysfunction
- Lactate  $< 3$
- No thromboembolism or bleeding Risk
- Anticoagulation at target

# BERLIN PROTOCOLS

## ECHO Protocol

Anticoagulate  
Stepwise VAD wean to 35bpm  
Hold 3-5 minutes  
ECHO / Lab checks

- Baseline
- Each VAD wean
- At 35 BPM, sit 10 min



## Cath Protocol

Anticoagulate  
Stepwise VAD wean to 35bpm  
Hold 3-5 minutes  
ECHO / Lab checks **PLUS**  
**RH Cath Hemodynamics + lactate, SVO2**

- Baseline
- Each VAD wean
- At 35 BPM, sit 10 min

**Turn VAD OFF**  
**Perfusion Hand pumps 6 bpm – wait 15 min**  
**ECHO, RHC**

# HM3 WEANING PROTOCOL

## 1. ECHO

6wks-2 months post VAD)

Min 4000 rpms

## 2. Exercise

1-2months post ECHO)

Failure =Symptomatic

Hypotension

Ectopy

Decreased function, MR

## 3. Cath

Goal < 1LPM without flow reversal

Conservation with RV VAD team

Echo Turndown Study

	Baseline				
Time					
RPMS	xxx				
Flow	xxx				
PI	xxx				
MAP	xxx				
RV function	xxx				
RV size	xxx				
RV EF	xxx				
Septal Position	xxx				
RV opening	xxx				
TR	xxx				
MR	xxx				
LVDD	xxx				
RVDD	xxx				
Comments					

# EXPLANT PREPARATION

## Dedicated Team

Surgeon /Surgical Team  
Cardiologists  
Nursing  
Perfusion  
Anesthesia  
ECHO

## Pre Explant Review Meeting

- Coordination
- Explant Team Huddle
- Surgical Consent
- Risks

# SURGERY

Sternotomy or Left anterior thoracotomy

ECHO

Heart Inspection

Bypass


VAD OFF

Disconnect outflow

Remove Inflow


Repair LV

Hemostasis



# SURGERY LV REPAIR

LV Apex Repair  
Primary  
Patch  
Plug






# HM3 PLUG




2019




CARDIOLOGY  
2025 

2021



CARDIOLOGY  
2025 

2024



CARDIOLOGY  
2025



# PRESENTATION & DIAGNOSIS

6 month old female New onset Heart Failure:

- tachycardia, tachypneic
- wt loss
- decreased urine
- troponin leak
- BNP >5000
- elevated Bun/Cr, AST, ALT
- Wide complex rhythm with LBBB pattern
- ECHO, CT, Consult

Day 2    Intubated  
          Discussed VAD  
          Chronic Resynchronization Therapy (CRT)



# SURGERY & POST OP

Day 3                      SURGERY  
VAD (10cc Berlin ) Bypass 99 min

=====

POD 1                    iNO, epi, dopa, milrinone  
ECHO

LV decompressed; good function

POD 2                    Extubated, Bivalirudin

POD 3 – 15            Off EPI/Dop/iNO  
ON sildenafil, Aldactone, Carvedilol  
Transfer to Cardiac Step Down



# VAD TURNDOWNS AND EXPLANT

2 months Post VAD



**ECHO turndown**

Ongoing wide QRS with LBBB  
Planned CRT



3.5 months post VAD  
**CATH Turndown**



5.5 months Post VAD  
**EXPLANT + CRT**




# POST VAD EXPLANT

POD 1 Extubated

POD3 ECHO  
NL LV function, mildly decreased ejection  
paradoxical septal motion  
Normal RV size and systolic shortening

POD 21 Discharged  
ECHO: Mild dilatation of LV  
NL LV systolic shortening  
Continue Cardiac Remodeling Medications  
Aldactone/ Enalapril/ Carvedilol  
DDD 80-180





# POST EXPLANT

Early VAD placement  
Medication Protocols  
VAD Wean Protocols  
CRT at time of VAD removal

Follow-up  
Regular Clinic Visits  
Medications  
ECHO  
Surveillance



# STEPS FOR SUCCESS

Commitment to Change  
Dedicated Teams  
Guideline Directed Medical Therapy  
Standardized weaning protocols  
Active surveillance  
Serial cardiac imaging  
Regular Explant Review  
Structured rehabilitation program



# ROAD TO EXPLANT

Active surveillance  
Guideline Directed Medical Therapy  
Standardized weaning protocols  
Concerted effort



# Thank you

# REFERENCES

- REFERENCES

1. Fraser CD Jr, Jaquiss RDB, Rosenthal DN, et al. Prospective trial of a pediatric ventricular assist device. *N Engl J Med* 2012; 9367(6): 532–541.
2. Selzman CH, Madden JL, Healy AH, et al. Bridge to removal: a paradigm shift for left ventricular assist device therapy. *Ann Thorac Surg*. 2015 Jan;99(1):360-7.
3. Ricklefs M, Deodhar C, Chatterjee A, et al. A new tool for an explantation strategy of HeartMate 3™ left ventricular assist device. *J Thorac Dis*. 2018 Jun;10(Suppl 15):S1825-28.
4. Baldwin AC, Sandoval E, Letsou GV, et al. Surgical approach to continuous-flow left ventricular assist device explantation: A comparison of outcomes. *J Thorac Cardiovasc Surg*. 2016 Jan;151(1):192
5. Medina, M, Alam, A, et al. HeartMate 3 Explantation Using Felt Plug for Ventriculotomy Occlusion. *Methodist DeBakey Cardiovasc J*. 2023 May 8;19(1):43–48.
6. DS Burstein, YSV Huang, et al. Trends in Bivalrudin Resource Utilization Among Young Ventricular Assist Device Recipients. *Circulation*, 2021 - Am Heart Assoc
7. Birks, E.J. · Drakos, S.G. · Patel, S.R. ...Prospective multicenter study of myocardial recovery using left ventricular assist devices (RESTAGE-HF [Remission from Stage D Heart Failure]): medium-term and primary end point results
8. Miera, O. · Germann, M. · Cho, M.Y. ...Bridge to recovery in children on ventricular assist devices-protocol, predictors of recovery, and long-term follow-up *J Heart Lung Transplant*. 2018; 37:1459-1466
9. Frazier, OH · Baldwin, ACW · Demirozu, ZT Ventricular reconditioning and pump explantation in patients supported by continuous-flow left ventricular assist devices *Heart Lung Transplant*. 2015; 34:766-772
10. Myocardial functional recovery following durable ventricular assist device in children.,Langanecha, Bhavikkumar et al.,JHLT Open, Volume 7, 100181